Key facts
- Cambiotics’s last known valuation is $21.1M (Feb 2026).
- It has raised $11.0M; the latest was Seed Round ($7.0M) in Feb 2026.
- Notable investors include Collaborative Fund, Denmark's Export and Investment Fund, Cambridge Enterprise Ventures, BioInnovation Institute, True. — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cambiotics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cambiotics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cambiotics
Developer of precision probiotics designed for per-and polyfluorinated substances detoxification from the body. The company's platform uses advanced biotechnology to create probiotics that can specifically target and neutralize chemicals, enabling individuals to potentially reduce their exposure to these persistent pollutants and improve their health.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2024
- Employees
- 9
- Website
- cambiotics.com/
- Ownership
- Privately Held (backing)
Cambiotics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cambiotics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cambiotics in its N-PORT filings yet. We sweep new filings monthly.